Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic Acid in Total Knee Arthroplasty: IV vs. Topical
NCT01940523Phase 4
Key facts
- Status
- Completed
- Start
- May 2013
- Primary completion
- Dec 2015
- Countries
- 1
- Sponsor
- Hospital for Special Surgery
- Modality
- Small Molecules
- Drugs
- tranexamic acid
- Conditions
- osteoarthritis (OA)
01
Overview
Phase 4, randomised, open-label trial of tranexamic acid in osteoarthritis (OA) (2 arms), sponsored by Hospital for Special Surgery. Primary endpoint: Total Blood Loss. Started May 2013; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Topical Tranexamic Acid
3g TXA in 75mL saline applied to joint surfaces for 5 mins before tourniquet release.
Intravenous Tranexamic Acid
1g IV TXA prior to tourniquet inflation + 1g IV TXA during closure.
03
Endpoints
Primary
Total Blood Loss
Secondary
Drain Output
The Number Patients Requiring a Transfusion
Beyond the preview
Go deeper on NCT01940523.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940523.